The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

Barbara Ensoli, Valeria Fiorelli, Fabrizio Ensoli, Adriano Lazzarin, Raffaele Visintini, Pasquale Narciso, Aldo Di Carlo, Paolo Monini, Mauro Magnani, Enrico Garaci

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.

Original languageEnglish
Pages (from-to)2207-2209
Number of pages3
JournalAIDS (London, England)
Volume22
Issue number16
DOIs
Publication statusPublished - 2008

Fingerprint

Human Immunodeficiency Virus tat Gene Products
HIV-1
Vaccines
Life Cycle Stages
Dendritic Cells
Haplorhini
Disease Progression
HIV
Viruses
Safety
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. / Ensoli, Barbara; Fiorelli, Valeria; Ensoli, Fabrizio; Lazzarin, Adriano; Visintini, Raffaele; Narciso, Pasquale; Di Carlo, Aldo; Monini, Paolo; Magnani, Mauro; Garaci, Enrico.

In: AIDS (London, England), Vol. 22, No. 16, 2008, p. 2207-2209.

Research output: Contribution to journalArticle

Ensoli, B, Fiorelli, V, Ensoli, F, Lazzarin, A, Visintini, R, Narciso, P, Di Carlo, A, Monini, P, Magnani, M & Garaci, E 2008, 'The therapeutic phase I trial of the recombinant native HIV-1 Tat protein', AIDS (London, England), vol. 22, no. 16, pp. 2207-2209. https://doi.org/10.1097/QAD.0b013e32831392d4
Ensoli, Barbara ; Fiorelli, Valeria ; Ensoli, Fabrizio ; Lazzarin, Adriano ; Visintini, Raffaele ; Narciso, Pasquale ; Di Carlo, Aldo ; Monini, Paolo ; Magnani, Mauro ; Garaci, Enrico. / The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. In: AIDS (London, England). 2008 ; Vol. 22, No. 16. pp. 2207-2209.
@article{98affc8f816747329bdd29fd6133deae,
title = "The therapeutic phase I trial of the recombinant native HIV-1 Tat protein",
abstract = "The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.",
author = "Barbara Ensoli and Valeria Fiorelli and Fabrizio Ensoli and Adriano Lazzarin and Raffaele Visintini and Pasquale Narciso and {Di Carlo}, Aldo and Paolo Monini and Mauro Magnani and Enrico Garaci",
year = "2008",
doi = "10.1097/QAD.0b013e32831392d4",
language = "English",
volume = "22",
pages = "2207--2209",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "16",

}

TY - JOUR

T1 - The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

AU - Ensoli, Barbara

AU - Fiorelli, Valeria

AU - Ensoli, Fabrizio

AU - Lazzarin, Adriano

AU - Visintini, Raffaele

AU - Narciso, Pasquale

AU - Di Carlo, Aldo

AU - Monini, Paolo

AU - Magnani, Mauro

AU - Garaci, Enrico

PY - 2008

Y1 - 2008

N2 - The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.

AB - The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.

UR - http://www.scopus.com/inward/record.url?scp=55249107608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249107608&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32831392d4

DO - 10.1097/QAD.0b013e32831392d4

M3 - Article

VL - 22

SP - 2207

EP - 2209

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 16

ER -